IL6 and congenital rubella syndrome: IL-6 antagonists such as tocilizumab and stutuzumab can block downstream signal transduction through receptor binding, effectively controlling CRS without affecting the efficacy of CAR-T cells (Maude et al., 2014; Wang et al., 2018a).